Table 5.
The Risk Factors of Metastases of Lung Cancer
| Author | Year | Histopathological Type | Metastatic Sites | Risk Factor |
|---|---|---|---|---|
| Morita et al20 | 2019 | NSCLC | Intertrabecular Vertebral | CEA |
| Zhou et al21 | 2017 | NS | Bone | CA-125, ALP |
| Liu et al22 | 2017 | Adenocarcinoma | Brain, lymph node | CYFRA21-1 |
| Wu et al23 | 2017 | NSCLC | Lymph node | MicroRNA-422a |
| Chu et al24 | 2017 | Adenocarcinoma | Lymph node | CLSTN1, CLU, NGAL |
| Chen et al25 | 2015 | NSCLC | Brain | NSE |
| Chen et al26 | 2015 | NS | Lymph node | CYFRA21-1, CEA |
| Lee et al27 | 2012 | NSCLC | Brain | CEA |
| Cabreraalarcon28 | 2011 | NS | NS | CYFRA21-1 |
| Cedrés29 | 2011 | NSCLC | Brain | CEA, CYFRA21-1, CA-125 |
| Oshiro et al30 | 2004 | Adenocarcinoma | Liver | AFP |
| Pollán et al31 | 2003 | NSCLC | NS | CA-125 |
| NiklińskiJ32 | 1992 | NSCLC | Lymph node | SCC |
Abbreviations: NS, not specific; NSCLC, non-small cell lung cancer; SCC, squamous cell carcinoma antigen; CLSTN1, calsyntenin-1; CLU, clusterin; NGAL, neutrophil gelatinase-associated lipocalin.